Dapzura Rt is a drug owned by Baxter Healthcare Corp. It is protected by 1 US drug patent filed in 2022 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 11, 2041. Details of Dapzura Rt's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11173189 | Daptomycin formulations containing a combination of sorbitol and mannitol |
Mar, 2041
(15 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Dapzura Rt's patents.
Latest Legal Activities on Dapzura Rt's Patents
Given below is the list of recent legal activities going on the following patents of Dapzura Rt.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail Pub Notice re 312 amendment | 28 Jul, 2022 | US11173189 |
| Email Notification Critical | 28 Jul, 2022 | US11173189 |
| POST ISSUE OTHER COMMUNICATION TO APPLICANT- CERTIFICATE OF CORRECTION | 23 Jul, 2022 | US11173189 |
| Post Issue Communication - Certificate of Correction Denied | 23 Jul, 2022 | US11173189 |
| Recordation of Patent Grant Mailed Critical | 16 Nov, 2021 | US11173189 |
| Patent Issue Date Used in PTA Calculation Critical | 16 Nov, 2021 | US11173189 |
| Email Notification Critical | 30 Oct, 2021 | US11173189 |
| Issue Notification Mailed Critical | 27 Oct, 2021 | US11173189 |
| Email Notification Critical | 20 Oct, 2021 | US11173189 |
| Mailing Corrected Notice of Allowability | 20 Oct, 2021 | US11173189 |
US patents provide insights into the exclusivity only within the United States, but Dapzura Rt is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Dapzura Rt's family patents as well as insights into ongoing legal events on those patents.
Dapzura Rt's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Dapzura Rt's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 11, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Dapzura Rt Generic API suppliers:
Daptomycin is the generic name for the brand Dapzura Rt. 19 different companies have already filed for the generic of Dapzura Rt, with Dr Reddys having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Dapzura Rt's generic
Alternative Brands for Dapzura Rt
Dapzura Rt which is used for treating bacterial infections., has several other brand drugs using the same active ingredient (Daptomycin). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Cubist Pharms Llc |
| ||
| Hikma |
| ||
| Hospira |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Daptomycin, Dapzura Rt's active ingredient. Check the complete list of approved generic manufacturers for Dapzura Rt
About Dapzura Rt
Dapzura Rt is a drug owned by Baxter Healthcare Corp. It is used for treating bacterial infections. Dapzura Rt uses Daptomycin as an active ingredient. Dapzura Rt was launched by Baxter Hlthcare Corp in 2022.
Approval Date:
Dapzura Rt was approved by FDA for market use on 25 January, 2022.
Active Ingredient:
Dapzura Rt uses Daptomycin as the active ingredient. Check out other Drugs and Companies using Daptomycin ingredient
Treatment:
Dapzura Rt is used for treating bacterial infections.
Dosage:
Dapzura Rt is available in powder form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 500MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | POWDER | Discontinued | INTRAVENOUS |